...
首页> 外文期刊>World neurosurgery >Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
【24h】

Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.

机译:当手术腔与脑室连通时进行卡莫斯汀晶片植入:临床系列的技术考虑。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Implantation of carmustine (1,3-bis (2 chloroetyl)-1-nitrosurea [BCNU]) wafers is an approved local treatment after surgical removal of high-grade gliomas. Safety data have been largely reported by phase III studies. The communication between the final surgical cavity and the ventricular cavities is supposed to be a relative contraindication for positioning of the wafers because of the possible development of hydrocephalus. However, at present there are neither data about this topic published with the exception of a few case reports, nor any proposals for selection criteria for wafer implantation in such circumstances. Furthermore, there are no technical suggestions in literature put forward for the surgical repairing of ventricular defects. Our study was particularly focused on addressing these 3 issues. METHODS: Forty-three patients affected by a high-grade glioma underwent surgical removal and BCNU wafer implantation between March 2007 and September 2009 at the Department of Neurosurgery of Padua. Among them, we retrospectively reviewed clinical, surgical, and radiological data of 9 patients who had been treated with carmustine wafers after surgical repair of communication between the surgical cavity and the ventricular cavities. We also focused on the technical details concerning wafers positioning in this particular situation. RESULTS: Ventricular defects were present in the atrium in 4, frontal horn in 3, and temporal horn in 2 cases. The maximum diameter of the defect was between 6 and 10 mm. In all cases, the defect was intraoperatively repaired in the same way, and up to 8 wafers were implanted in the surgical cavity. In the series reported, no cases of hydrocephalus were detected. CONCLUSIONS: In our experience, integrity of wafers, size of ventricular wall defect, and accuracy in repairing the defect were crucial issues. Nevertheless, more experience and prospective studies would be helpful to clarify both in what measure ventricular opening affects safety data and the best reliable way of repairing ventricular defects when BCNU wafers are implanted.
机译:背景:卡莫司汀(1,3-双(2氯乙基)-1-硝基脲[BCNU])晶片的植入是手术切除高级别神经胶质瘤后的一种公认的局部治疗方法。第三阶段研究报告了安全数据。由于脑积水的可能发展,最终手术腔和心室腔之间的连通被认为是晶片定位的相对禁忌症。但是,目前除了少数病例报告外,没有发表有关该主题的数据,在这种情况下也没有任何关于晶圆植入选择标准的建议。此外,文献中没有针对心室缺损的手术修复的技术建议。我们的研究特别关注解决这三个问题。方法:2007年3月至2009年9月之间,在帕多瓦神经外科接受了高级别神经胶质瘤影响的43例患者的手术切除和BCNU晶片植入术。其中,我们回顾性分析了9例在手术腔室与心室腔之间的通信修复后接受卡莫司汀片治疗的患者的临床,手术和放射学数据。我们还专注于在这种特定情况下有关晶片定位的技术细节。结果:4例中庭出现心室缺损,额角3例,颞角2例。缺陷的最大直径在6到10毫米之间。在所有情况下,均以相同的方式对缺损进行术中修复,并在手术腔中植入多达8个晶片。在报告的系列中,未发现脑积水病例。结论:根据我们的经验,晶片的完整性,心室壁缺损的大小以及修复缺损的准确性是至关重要的问题。然而,更多的经验和前瞻性研究将有助于阐明在何种程度上心室张开会影响安全性数据以及在植入BCNU晶片时修复心室缺损的最佳可靠方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号